COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome
- PMID: 32508329
- PMCID: PMC7369032
- DOI: 10.3233/JND-200520
COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome
Abstract
This is a brief report of a patient who has refractory Myasthenia Gravis, on multiple long-term immunosuppressive therapies and contracted COVID-19 during this 2020 pandemic. She was quarantined for total of 14 days and recovered successfully without any complications (no myasthenia exacerbation or crisis, no COVID-19 related complications), with no changes to her immunosuppressive therapy. Treatment of MG patients with COVID-19 needs to be tailored to individual patient.
Keywords: COVID-19; Plasmapheresis; Refractory Myasthenia Gravis; immunosuppression; outcome.
Conflict of interest statement
The authors have no conflict of interest to report.
References
-
- Ciafaloni E. Myasthenia Gravis and Congenital Myasthenic syndromes. Continuum (Minneap Minn). 2019;25(6):1767–84. - PubMed
-
- Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023–36. - PubMed
-
- Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2570–2581. - PubMed
-
- Gilhus NE, Nacu A, Andersen JB, Owe JF. Myasthenia gravis and risks for comorbidity. Eur J Neurol. 2015;22:17–23. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
